Williams K Hagmann Selected Research

Weight Loss (Weight Reduction)

6/2007

Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Williams K Hagmann Research Topics

Disease

1	Body Weight (Weight, Body) 06/2007
1	Obesity 06/2007
1	Weight Gain 06/2007
1	Weight Loss (Weight Reduction) 06/2007

Drug/Important Bio-Agent (IBA)

1	N- (3- (4- chlorophenyl)- 2- (3- cyanophenyl)- 1- methylpropyl)- 2- methyl- 2- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)propanamideIBA 06/2007